

# Tetrabenazine

Catalog No: tcsc2801

Membrane Transporter/Ion Channel

Target:

Monoamine Transporter

## Purity / Grade:

>98%

## Solubility:

DMSO : ≥ 3.2 mg/mL (10.08 mM)

#### **Alternative Names:**

Ro 1-9569

### **Observed Molecular Weight:**

317.42

Copyright 2021 Taiclone Biotech Corp.




## **Product Description**

Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.

#### Target: Others

tetrabenazine (TBZ), a monoamine-depleting and a dopamine-receptor-blocking drug. TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders. In contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia [1, 2]. Twenty patients with tardive dyskinesia (mean duration = 43.7 months) were videotaped before and after tetrabenazine treatment. One patient did not tolerate tetrabenazine owing to sedation. The remaining 19 were rated after a mean of 20.3 weeks at a mean tetrabenazine dose of 57.9 mg/day. There were significant improvements in mean scores on both the patient AIMS self-rating and the AIMS motor subset evaluated by the blind videotape raters. All 19 patients continued to take tetrabenazine after the study [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.